Eyevensys Names Ronald Buggage as Chief Medical Officer

September 8, 2017: By Jon Swedien

eyevensysEyevensys has appointed Ronald Buggage, MD, its chief medical officer, the French company announced Sept. 4.

Eyevensys is a private clinical stage biotech company based in Paris. The company is developing its proprietary EyeCET platform, which it says is the first non-viral gene expression technology that enables safe, local, sustained production of therapeutic proteins in the eye to address a wide range of ophthalmic diseases.

Buggage will drive the company’s drug development strategy, overseeing clinical development programs for a broad range of ophthalmic indications based on the EyeCET platform.

Buggage was most recently division medical officer at Sanofi’s Ophthalmology Unit, Eyevensys said. He was responsible for coordination of medical and scientific activities for Sanofi’s ophthalmology portfolio, including development programs for ocular gene therapy.

He has also served as chief scientific officer at Novagali Pharma, where he was responsible for the global clinical and regulatory strategy.

Buggage has also held positions in clinical development at Novartis and Pfizer. He obtained his doctorate at the UCLA School of Medicine and specialized in ophthalmology at Emory University. He completed his training in ocular immunology and uveitis at the National Eye Institute of the National Institutes of Health.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023